Glaucoma News

Protect Your Vision: Essential Eye Health Tips for Prevention of Blindness Week Every year, Prevention of Blindness Week serves as a crucial reminder of a startling fact: up to 80% of all vision impairment is avoidable. From simple lifestyle adjustments to proactive medical care, the power to protect our sight lies largely in our own […]

Immunovant’s Eye Disease Drug Fails Pivotal Phase 3 Trial In a significant setback for patients and the biotech company, Immunovant has announced that its investigational drug for thyroid eye disease (TED) failed to meet its primary endpoint in a crucial Phase 3 clinical trial. The news, released on April 2, 2026, sent shockwaves through the

Sight Sciences to Showcase Glaucoma and Dry Eye Innovations at ASCRS 2026 The landscape of ophthalmic care is poised for a significant update as Sight Sciences, Inc. prepares to take center stage at the upcoming 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The company has announced that its portfolio of interventional

Marine Animal Virus Triggers Mysterious Human Eye Infections In a startling discovery that blurs the lines between marine biology and human medicine, scientists have identified a virus common in marine animals as the culprit behind a series of mysterious and severe eye infections in people. This finding, reported by New Scientist, reveals a previously unknown

AI Eye Exams Predict Heart Disease Risk in Routine Checkups For decades, the routine eye exam has been a window to the soul of our vision health. But what if that same quick, non-invasive look could also reveal the secrets of your heart? Groundbreaking new research suggests that artificial intelligence (AI), trained to analyze scans

Viridian Stock Crashes 34% After Eye Drug Efficacy Disappoints The brutal reality of biotech investing was on full display this week as Viridian Therapeutics saw its stock price plunge by a staggering 34% in a single day. The catalyst? Clinical trial results for its promising eye disease drug, VRDN-001, which delivered a paradoxical blow: it

Viridian’s Thyroid Eye Disease Drug Stumbles, Stock Plummets 30% The race to challenge Amgen’s blockbuster thyroid eye disease (TED) drug, Tepezza, just hit a major roadblock. Viridian Therapeutics, a biotech firm that had been gaining significant attention from investors, saw its stock price crater by over 30% following the release of disappointing early-stage clinical trial

Viridian’s Elegrobart Succeeds in Phase 3 Thyroid Eye Disease Trial In a significant breakthrough for patients with Thyroid Eye Disease (TED), Viridian Therapeutics has announced positive topline results from its pivotal Phase 3 REVEAL1 clinical trial. The trial evaluated the efficacy and safety of elegrobart, the company’s novel investigational monoclonal antibody, in treating active, moderate-to-severe

Ultra-Processed Foods Linked to Heart Disease and Glaucoma Risk For years, nutritionists have urged us to “eat clean” and avoid packaged snacks and ready-made meals. Now, a powerful new study provides some of the strongest evidence yet that this advice is not just about waistlines—it’s a matter of life and death for your heart and

Kodiak Sciences’ Positive Eye Disease Data: Should Investors Buy the Rally? The biotech sector is no stranger to dramatic swings, and Kodiak Sciences Inc. (KOD) just provided a textbook example. After announcing positive topline data from its pivotal GLEAM and GLIMMER studies for its lead candidate, **tarcocimab tedromer**, in diabetic eye diseases, the company’s stock